Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Published:2024-07-24 Issue:5 Volume:13 Page:1385-1401
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Wiendl Heinz,Foley John,Defer Gilles,Zhovtis Ryerson Lana,Cohen Jeffrey A.,Arnold Douglas L.,Butzkueven Helmut,Cutter Gary R.,Giovannoni Gavin,Killestein Joep,Domingo-Horne Rose,Toukam Marie,Nunn Aimie,Maghzi Amir-Hadi,Kuhelj Robert,Lasky Tyler

Funder

Biogen

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40120-024-00647-0.pdf

Reference24 articles.

1. Jackson Y, Janssen E, Fischer R, et al. The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management. Expert Rev Pharmacoecon Outcomes Res. 2019;19(4):383–96.

2. Tysabri (natalizumab) [prescribing information]. Biogen Inc. Cambridge.

3. FDA approves Tysabri. 2004. https://www.drugs.com/newdrugs/tysabri-approved-multiple-sclerosis-162.html. Accessed 31 Oct 2023

4. Simonsen CS, Flemmen H, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front Neurol. 2021;12: 693017.

5. Tysabri: EPAR—product information. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri#product-information-section. Accessed 1 Nov 2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP